Evidence map›Paper›PMID 29225665›Full record

ArticleNano today2017

Evolution and Clinical Translation of Drug Delivery Nanomaterials.

Shabir Hassan, Gyan Prakash, Aycabal Ozturk, Saghi Saghazadeh, Mohammad Farhan Sohail, Jungmok Seo, Mehmet Dockmeci, Yu Shrike Zhang, Ali Khademhosseini

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nano today, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers.

0numbers the graph read from it
0cells of the map it votes in
80citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

80 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review

20 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Shabir HassanBiomaterials Innovation Research Center, Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA 02139, USA.
Gyan PrakashBiomaterials Innovation Research Center, Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA 02139, USA.
Aycabal OzturkBiomaterials Innovation Research Center, Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA 02139, USA.
Saghi SaghazadehBiomaterials Innovation Research Center, Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA 02139, USA.
Mohammad Farhan SohailBiomaterials Innovation Research Center, Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA 02139, USA.
Jungmok SeoBiomaterials Innovation Research Center, Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA 02139, USA.
Mehmet DockmeciBiomaterials Innovation Research Center, Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA 02139, USA.
Yu Shrike ZhangBiomaterials Innovation Research Center, Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA 02139, USA.
Ali KhademhosseiniBiomaterials Innovation Research Center, Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA 02139, USA.

Funding

Microengineered Osteons for Bone Tissue EngineeringR01AR057837 · NIAMS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI YANG, YUNZHI · 2010 to 2018
$5.1M
Targeted chemotherapy delivery and captureR01EB024403 · NIBIB · MAYO CLINIC ARIZONA · PI KHADEMHOSSEINI, ALI, OKLU, RAHMI · 2017 to 2020
$2.2M
High-Throughput Microenvironment Regulation for ChondrogenesisR01AR066193 · NIAMS · UNIVERSITY OF ILLINOIS AT CHICAGO · PI ALSBERG, EBEN, KHADEMHOSSEINI, ALI · 2015 to 2020
$2.1M
Engineering Vascularized Bone Tissues By Microfabrication And ScaffoldingR01DE021468 · NIDCR · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI YANG, YUNZHI · 2011 to 2014
$1.8M
Catheter guided endovascular electric field ablation for thrombosis therapy.R21EB021148 · NIBIB · MAYO CLINIC ARIZONA · PI KHADEMHOSSEINI, ALI, OKLU, RAHMI · 2016 to 2017
$485k
Smart wound dressing for treating chronic diabetic ulcersR21EB022403 · NIBIB · BRIGHAM AND WOMEN'S HOSPITAL · PI KHADEMHOSSEINI, ALI · 2016 to 2017
$484k
Angiogenic Biomaterials as Dermal Scaffolds to Enhance Diabetic Wound HealingR21AR068258 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI KHADEMHOSSEINI, ALI · 2015 to 2016
$412k
Recapitulating Ductal Carcinoma on a Chip for Personalized Breast Cancer TherapyK99CA201603 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ZHANG, Y. SHRIKE · 2016 to 2017
$356k
NCI NIH HHS K99 CA201603NIAMS NIH HHS R01 AR057837NIAMS NIH HHS R01 AR066193NIAMS NIH HHS R21 AR068258NIBIB NIH HHS R01 EB024403NIBIB NIH HHS R21 EB021148NIBIB NIH HHS R21 EB022403NIDCR NIH HHS R01 DE021468
6 · The paper itself

Abstract

With the advent of technology, the role of nanomaterials in medicine has grown exponentially in the last few decades. The main advantage of such materials has been exploited in drug delivery applications, due to their effective targeting that in turn reduces systemic toxicity compared to the conventional routes of drug administration. Even though these materials offer broad flexibility based on targeting tissue, disease, and drug payload, the demand for more effective yet highly biocompatible nanomaterial-based drugs is increasing. While therapeutically improved and safe materials have been introduced in nanomedicine platforms, issues related to their degradation rates and bio-distribution still exist, thus making their successful translation for human use very challenging. Researchers are constantly improving upon novel nanomaterials that are safer and more effective not only as therapeutic agents but as diagnostic tools as well, making the research in the field of nanomedicine ever more fascinating. In this review stress has been made on the evolution of nanomaterials that have been approved for clinical applications by the United States Food and Drug Administration Agency (FDA).

Indexed as

Clinical trialsDrug deliveryFDA approvalInorganic nanomaterialLiposomesPolymeric nanomaterial

Identifiers

PMID29225665
PMCPMC5720147

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.